RNASeq profiling of COVID19-infected patients identified an EIF2AK2 inhibitor as a potent SARS-CoV-2 antiviral.
Sidharth JainSamantha RegoSteven ParkYiran LiuSimone ParnKush SavsaniDavid S PerlinSivanesan DakshanamurthyPublished in: Clinical and translational medicine (2022)